The Correlation of Glial Fibrillary Acid Protein Level to Cognitive Function Outcome in Acute Lacunar Ischemic Stroke Patient

Dodik Tugasworo; Locoporta Agung; Retnaningsih Retnaningsih; Amin Husni; Aris Catur Bintoro; Arinta Puspita Wati

doi:10.3889/oamjms.2023.11393

Authors

Dodik Tugasworo Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia
Locoporta Agung Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia https://orcid.org/0000-0002-9156-8552
Retnaningsih Retnaningsih Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia
Amin Husni Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia
Aris Catur Bintoro Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia
Arinta Puspita Wati Department of Neurology, Faculty of Medicine, Diponegoro University, DR. Kariadi General Hospital Center, Semarang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2023.11393

Keywords:

Cognitive, Glial fibrillary acidic protein, lacunar ischemic stroke, MoCA Ina

Abstract

ABSTRACT :

Introduction : Glial fibrillary acidic protein (GFAP) is a filamentous protein found in central nervous system astrocytes. Increased serum GFAP levels are caused by the process of astrogliosis after ischemic stroke and are associated with multisynaptic disorders so that they are at risk of causing cognitive disorders.

Objective: To analyze the correlation between GFAP levels and cognitive function output in acute lacunar ischemic stroke patients.

Research Methods : Analytical observational with prospective cohort approach. The subjects of this study were Acute lacunar ischemic stroke patients with mild to moderate NIHSS scores. Serum GFAP levels were taken at the onset of 48-72 hours of stroke. Cognitive function was measured using the Indonesian version of MoCA (MoCA Ina) test on the seventh and thirtieth day. Bivariate and multivariate analyzes were performed to assess the correlation between GFAP levels, cognitive functions and the confounding factors.

Results: There was a significant correlation between GFAP levels and the MoCA Ina scores on the seventh day (r= -0.32, p=0.044), the thirtieth day (r= -0.398, p=0.011), and improvement in MoCA Ina scores (r= -0.342, p = 0.031). There was a significant correlation between GFAP levels on the executive domain on the seventh day (p= 0.01) and thirtieth day (p= 0.005), visuospatial on seventh day (p= 0.004) and thirtieth day (p= 0.016), language on the thirtieth day (p = 0.005), and memory on thirtieth day (p= 0.001). There was no significant correlation between GFAP levels and improvements in attentional, memory, language, visuospatial, and executive domains.

Conclusion: There was a significant correlation between GFAP levels and MoCA Ina scores on the seventh, thirtieth day and the improvement of MoCA Ina scores. There was a significant correlation between GFAP levels with the executive, visuospatial, language, and memory domains.

Keywords: cognitive, GFAP, lacunar ischemic stroke, MoCA Ina

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ropper AH, Samuels MA, Klein JP. Adams and Victor’s Principles of Neurology. 10th ed. New York: The McGraw-Hill Education; 2015. p. 778.

Minister of Health of the Republic of Indonesia. National Guidelines for Stroke Management Medical Services. Jakarta: Kementrian Kesehatan; 2019. p. 14. [Indonesia].

Pokdi Stroke. Stroke Guidelines. Jakarta: PERDOSSI; 2011. p. 14. [Indonesia].

Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. Neuroinflammation: Friend and foe for ischemic stroke. J Neuroinflammation. 2019;16(1):142. https://doi.org/10.1186/s12974-019-1516-2 PMid:31291966 DOI: https://doi.org/10.1186/s12974-019-1516-2

Wall HK, Beagan BM, O’Neill HJ, Foell KM, Boddie-Willis CL. Addressing stroke signs and symptoms through public education: The Stroke Heroes Act FAST campaign. Prev Chronic Dis. 2008;5(2):A49. PMid:18341784

Vakhnina NV, Nikitina LY, Parfenov VA, Yakhno NN. Post-stroke cognitive impairments. Neurosci Behav Physiol. 2009;39(8):719-24. https://doi.org/10.1007/s11055-009-9198-3 PMid:19779824 DOI: https://doi.org/10.1007/s11055-009-9198-3

Salvadori E, Pasi M, Poggesi A, Chiti G, Inzitari D, Pantoni L. Predictive value of MoCA in the acute phase of stroke on the diagnosis of mid-term cognitive impairment. J Neurol. 2013;260(9):2220-7. https://doi.org/10.1007/s00415-013-6962-7 PMid:23716072 DOI: https://doi.org/10.1007/s00415-013-6962-7

Jacquin A, Binquet C, Rouaud O, Graule-Petot A, Daubail B, Osseby GV, et al. Post-stroke cognitive impairment: High prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40(4):1029-38. https://doi.org/10.3233/JAD-131580 PMid:24577459 DOI: https://doi.org/10.3233/JAD-131580

Danovska M, Peychinska D. Post-stroke cognitive impairment-phenomenology and prognostic factors. J IMAB Annu Proc Sci Pap. 2012;18(3):290-7. https://doi.org/10.5272/jimab.2012183.290 DOI: https://doi.org/10.5272/jimab.2012183.290

Pasi M, Poggesi A, Salvadori E, Pantoni L. Post-stroke dementia and cognitive impairment. Front Neurol Neurosci. 2012;30:65-9. https://doi.org/10.1159/000333412 PMid:22377866 DOI: https://doi.org/10.1159/000333412

Yang Z, Wang KK. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364-74. https://doi.org/10.1016/j.tins.2015.04.003 PMid:25975510 DOI: https://doi.org/10.1016/j.tins.2015.04.003

Wahul AB, Joshi PC, Kumar A, Chakravarty S. Association of diagnostic stroke biomarkers with post stroke cognitive impairment. J Neurol Disord Stroke. 2018;6(1):1134.

Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis. 2014;6:51-8. https://doi.org/10.4137/JCNSD.S13821 PMid:24932109 DOI: https://doi.org/10.4137/JCNSD.S13821

Anderson BJ, Reilly JP, Ittner C, Johansson E, Dunn TG, McCarthy M, et al. Glial Fibrillary Acidic Protein (GFAP) is an early marker of cognitive impairment in sepsis survivors. In: B22. Critical Care: Microbiome, Genetics, and Other Biomarkers in Acute Critical Illness. New York: American Thoracic Society; 2018. p. A2780.

El Sherif M, Esmael A, Salam OA. Diagnostic and prognostic significance of blood biomarkers in acute ischemic stroke. Int Neuropsychiatr Dis J. 2016;6(1):1-11. https://doi.org/10.9734/INDJ/2016/22766 DOI: https://doi.org/10.9734/INDJ/2016/22766

Sarfo FS, Owusu D, Adamu S, Awuah D, Appiah L, Amamoo M, et al. Plasma glial fibrillary acidic protein, copeptin, and matrix metalloproteinase-9 concentrations among West African stroke subjects compared with stroke-free controls. J Stroke Cerebrovasc Dis. 2018;27(3):633-44. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.035 PMid:29074065 DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.035

Dagonnier M, Donnan GA, Davis SM, Dewey HM, Howells DW. Acute stroke biomarkers: Are we there yet? Front Neurol. 2021;12:619721. https://doi.org/10.3389/fneur.2021.619721 PMid:33633673 DOI: https://doi.org/10.3389/fneur.2021.619721

Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915-25. https://doi.org/10.1016/j.bbadis.2016.01.015 PMid:26806700 DOI: https://doi.org/10.1016/j.bbadis.2016.01.015

Mijajlović MD, Pavlović A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, et al. Post-stroke dementia-a comprehensive review. BMC Med. 2017;15(1):1-12. https://doi.org/10.1186/s12916-017-0779-7 PMid:28095900 DOI: https://doi.org/10.1186/s12916-017-0779-7

Jellinger KA, Attems J. Prevalance and pathology of vascular dementia in the oldest-old. J Alzheimers Dis. 2010;21(4):1283-93. https://doi.org/10.3233/jad-2010-100603 PMid:21504129 DOI: https://doi.org/10.3233/JAD-2010-100603

Cumming T, Brodtmann A. Dementia and stroke: The present and future epidemic. Int J Stroke. 2010;5(6):453-4. https://doi.org/10.1111/j.1747-4949.2010.00527.x PMid:21050400 DOI: https://doi.org/10.1111/j.1747-4949.2010.00527.x

Arboix A. Lacunar infarct and cognitive decline. Expert Rev Neurother. 2011;11(9):1251-4. https://doi.org/10.1586/ern.11.118 PMid:21864071 DOI: https://doi.org/10.1586/ern.11.118

Bettcher BM, Olson KE, Carlson NE, McConnell BV, Boyd T, Adame V, et al. Astrogliosis and episodic memory in late life: Higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer’s disease. Neurobiol Aging. 2021;103:68-77. https://doi.org/10.1016/j.neurobiolaging.2021.02.012 PMid:33845398 DOI: https://doi.org/10.1016/j.neurobiolaging.2021.02.012

Shir D, Graff-Radford J, Hofrenning EI, Lesnick TG, Przybelski SA, Lowe VJ, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer’s disease and vascular pathology. Alzheimers Dement (Amst). 2022;14(1):e12291. https://doi.org/10.1002/dad2.12291 PMid:35252538 DOI: https://doi.org/10.1002/dad2.12291

Gonzales MM, Wang CP, Short MI, Parent DM, Kautz T, MacCarthy D, et al. Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. Alzheimers Dement (Amst). 2022;14(1):e12298. https://doi.org/10.1002/dad2.12298 PMid:35356487 DOI: https://doi.org/10.1002/dad2.12298

Huang KL, Hsiao IT, Ho MY, Hsu JL, Chang YJ, Chang TY, et al. Investigation of reactive astrogliosis effect on post-stroke cognitive impairment. J Neuroinflammation. 2020;17(1):308. DOI: https://doi.org/10.1186/s12974-020-01985-0

Verberk IM, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: A prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2(2):e87-95. https://doi.org/10.1016/S2666-7568(20)30061-1 PMid:36098162 DOI: https://doi.org/10.1016/S2666-7568(20)30061-1

Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: Disease cause or consequence? J Cereb Blood Flow Metab. 2012;32(7):1207-21. https://doi.org/10.1038/jcbfm.2012.25 PMid:22395208 DOI: https://doi.org/10.1038/jcbfm.2012.25

Asken BM, VandeVrede L, Rojas JC, Fonseca C, Staffaroni AM, Elahi FM, et al. Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment. J Int Neuropsychol Soc. 2022;28(6):588-99. https://doi.org/10.1017/S1355617721000813 PMid:34158138 DOI: https://doi.org/10.1017/S1355617721000813

Venkat P, Shen Y, Chopp M, Chen J. Cell-based and pharmacological neurorestorative therapies for ischemic stroke. Neuropharmacology. 2018;134(Pt B):310-22. https://doi.org/10.1016/j.neuropharm.2017.08.036 PMid:28867364 DOI: https://doi.org/10.1016/j.neuropharm.2017.08.036

Levine DA, Wadley VG, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, et al. Risk factors for poststroke cognitive decline: The REGARDS study (reasons for geographic and racial differences in stroke). Stroke. 2018;49(4):987-94. https://doi.org/10.1161/STROKEAHA.117.018529 PMid:29581343 DOI: https://doi.org/10.1161/STROKEAHA.117.018529

Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, et al. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology. 2019;93(24):e2257-71. https://doi.org/10.1212/WNL.0000000000008612 PMid:31712368 DOI: https://doi.org/10.1212/WNL.0000000000008612

Kartikasari W, Retnaningsih R, Husni A. Correlation between serum S100b level and neurological clinical outcome in acute ischemic stroke patient. Majalah Kedokteran Neurosains. 2018;36(1):64-71. https://doi.org/10.52386/neurona.v36i1.55 DOI: https://doi.org/10.52386/neurona.v36i1.55